The Significance of CD44 Variant 9 in Resected Lung Adenocarcinoma: Correlation with Pathological Early-Stage and EGFR Mutation

Takaki Akamine, Tetsuzo Tagawa, Kayo Ijichi, Gouji Toyokawa, Shinkichi Takamori, Fumihiko Hirai, Tatsuro Okamoto, Yoshinao Oda, Yoshihiko Maehara

Research output: Contribution to journalArticle

Abstract

Background: CD44 isoforms serve as a marker for cancer stem cells. CD44 variant 9 (CD44v9) contributes to the defense against reactive oxygen species, resulting in resistance to chemoradiotherapy. However, the significance of CD44v9 in patients with lung adenocarcinoma is unknown. Methods: We used immunohistochemical analysis to retrospectively analyze CD44v9 expression in 268 surgically resected lung adenocarcinomas and investigated the association between CD44v9 expression and patients’ clinicopathological features. Results: The expression of CD44v9 in 193 of 268 (72.0%) patients was significantly associated with early-stage cancer, low-grade tumors, absence of vessel and pleural invasion, and a mutated epidermal growth factor receptor (EGFR) gene. Multivariate logistic analysis revealed that CD44v9 expression was significantly associated with early-stage disease [odds ratio (OR) 0.29, 95% confidence interval (CI) 0.14–0.59; p < 0.001] and mutant EGFR (OR 2.53, 95% CI 1.06–6.04; p = 0.036). The percentage of CD44v9-positive tumors was higher in the earlier stages of disease; however, there was no significant difference in the survival of patients in each stage of disease who had positive or negative CD44v9 expression. Conclusion: CD44v9 was highly expressed in EGFR-mutant tumors, particularly in early-stage lung adenocarcinoma, suggesting that CD44v9 expression may play an important role in EGFR-mutant tumors.

Original languageEnglish
Pages (from-to)1544-1551
Number of pages8
JournalAnnals of Surgical Oncology
Volume26
Issue number5
DOIs
Publication statusPublished - May 15 2019

Fingerprint

Epidermal Growth Factor Receptor
Mutation
Neoplasms
Odds Ratio
Confidence Intervals
erbB-1 Genes
Neoplastic Stem Cells
Chemoradiotherapy
Reactive Oxygen Species
Protein Isoforms
Multivariate Analysis
Adenocarcinoma of lung
Survival

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

The Significance of CD44 Variant 9 in Resected Lung Adenocarcinoma : Correlation with Pathological Early-Stage and EGFR Mutation. / Akamine, Takaki; Tagawa, Tetsuzo; Ijichi, Kayo; Toyokawa, Gouji; Takamori, Shinkichi; Hirai, Fumihiko; Okamoto, Tatsuro; Oda, Yoshinao; Maehara, Yoshihiko.

In: Annals of Surgical Oncology, Vol. 26, No. 5, 15.05.2019, p. 1544-1551.

Research output: Contribution to journalArticle

Akamine, Takaki ; Tagawa, Tetsuzo ; Ijichi, Kayo ; Toyokawa, Gouji ; Takamori, Shinkichi ; Hirai, Fumihiko ; Okamoto, Tatsuro ; Oda, Yoshinao ; Maehara, Yoshihiko. / The Significance of CD44 Variant 9 in Resected Lung Adenocarcinoma : Correlation with Pathological Early-Stage and EGFR Mutation. In: Annals of Surgical Oncology. 2019 ; Vol. 26, No. 5. pp. 1544-1551.
@article{03e94e538c924aad993b5b31172393c4,
title = "The Significance of CD44 Variant 9 in Resected Lung Adenocarcinoma: Correlation with Pathological Early-Stage and EGFR Mutation",
abstract = "Background: CD44 isoforms serve as a marker for cancer stem cells. CD44 variant 9 (CD44v9) contributes to the defense against reactive oxygen species, resulting in resistance to chemoradiotherapy. However, the significance of CD44v9 in patients with lung adenocarcinoma is unknown. Methods: We used immunohistochemical analysis to retrospectively analyze CD44v9 expression in 268 surgically resected lung adenocarcinomas and investigated the association between CD44v9 expression and patients’ clinicopathological features. Results: The expression of CD44v9 in 193 of 268 (72.0{\%}) patients was significantly associated with early-stage cancer, low-grade tumors, absence of vessel and pleural invasion, and a mutated epidermal growth factor receptor (EGFR) gene. Multivariate logistic analysis revealed that CD44v9 expression was significantly associated with early-stage disease [odds ratio (OR) 0.29, 95{\%} confidence interval (CI) 0.14–0.59; p < 0.001] and mutant EGFR (OR 2.53, 95{\%} CI 1.06–6.04; p = 0.036). The percentage of CD44v9-positive tumors was higher in the earlier stages of disease; however, there was no significant difference in the survival of patients in each stage of disease who had positive or negative CD44v9 expression. Conclusion: CD44v9 was highly expressed in EGFR-mutant tumors, particularly in early-stage lung adenocarcinoma, suggesting that CD44v9 expression may play an important role in EGFR-mutant tumors.",
author = "Takaki Akamine and Tetsuzo Tagawa and Kayo Ijichi and Gouji Toyokawa and Shinkichi Takamori and Fumihiko Hirai and Tatsuro Okamoto and Yoshinao Oda and Yoshihiko Maehara",
year = "2019",
month = "5",
day = "15",
doi = "10.1245/s10434-018-07137-2",
language = "English",
volume = "26",
pages = "1544--1551",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "5",

}

TY - JOUR

T1 - The Significance of CD44 Variant 9 in Resected Lung Adenocarcinoma

T2 - Correlation with Pathological Early-Stage and EGFR Mutation

AU - Akamine, Takaki

AU - Tagawa, Tetsuzo

AU - Ijichi, Kayo

AU - Toyokawa, Gouji

AU - Takamori, Shinkichi

AU - Hirai, Fumihiko

AU - Okamoto, Tatsuro

AU - Oda, Yoshinao

AU - Maehara, Yoshihiko

PY - 2019/5/15

Y1 - 2019/5/15

N2 - Background: CD44 isoforms serve as a marker for cancer stem cells. CD44 variant 9 (CD44v9) contributes to the defense against reactive oxygen species, resulting in resistance to chemoradiotherapy. However, the significance of CD44v9 in patients with lung adenocarcinoma is unknown. Methods: We used immunohistochemical analysis to retrospectively analyze CD44v9 expression in 268 surgically resected lung adenocarcinomas and investigated the association between CD44v9 expression and patients’ clinicopathological features. Results: The expression of CD44v9 in 193 of 268 (72.0%) patients was significantly associated with early-stage cancer, low-grade tumors, absence of vessel and pleural invasion, and a mutated epidermal growth factor receptor (EGFR) gene. Multivariate logistic analysis revealed that CD44v9 expression was significantly associated with early-stage disease [odds ratio (OR) 0.29, 95% confidence interval (CI) 0.14–0.59; p < 0.001] and mutant EGFR (OR 2.53, 95% CI 1.06–6.04; p = 0.036). The percentage of CD44v9-positive tumors was higher in the earlier stages of disease; however, there was no significant difference in the survival of patients in each stage of disease who had positive or negative CD44v9 expression. Conclusion: CD44v9 was highly expressed in EGFR-mutant tumors, particularly in early-stage lung adenocarcinoma, suggesting that CD44v9 expression may play an important role in EGFR-mutant tumors.

AB - Background: CD44 isoforms serve as a marker for cancer stem cells. CD44 variant 9 (CD44v9) contributes to the defense against reactive oxygen species, resulting in resistance to chemoradiotherapy. However, the significance of CD44v9 in patients with lung adenocarcinoma is unknown. Methods: We used immunohistochemical analysis to retrospectively analyze CD44v9 expression in 268 surgically resected lung adenocarcinomas and investigated the association between CD44v9 expression and patients’ clinicopathological features. Results: The expression of CD44v9 in 193 of 268 (72.0%) patients was significantly associated with early-stage cancer, low-grade tumors, absence of vessel and pleural invasion, and a mutated epidermal growth factor receptor (EGFR) gene. Multivariate logistic analysis revealed that CD44v9 expression was significantly associated with early-stage disease [odds ratio (OR) 0.29, 95% confidence interval (CI) 0.14–0.59; p < 0.001] and mutant EGFR (OR 2.53, 95% CI 1.06–6.04; p = 0.036). The percentage of CD44v9-positive tumors was higher in the earlier stages of disease; however, there was no significant difference in the survival of patients in each stage of disease who had positive or negative CD44v9 expression. Conclusion: CD44v9 was highly expressed in EGFR-mutant tumors, particularly in early-stage lung adenocarcinoma, suggesting that CD44v9 expression may play an important role in EGFR-mutant tumors.

UR - http://www.scopus.com/inward/record.url?scp=85062016516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062016516&partnerID=8YFLogxK

U2 - 10.1245/s10434-018-07137-2

DO - 10.1245/s10434-018-07137-2

M3 - Article

C2 - 30798450

AN - SCOPUS:85062016516

VL - 26

SP - 1544

EP - 1551

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 5

ER -